Showing 1 - 10 results of 10 for search 'Neal D Shore', query time: 0.04s Refine Results
  1. 1
    Experience with degarelix in the treatment of prostate cancer

    Experience with degarelix in the treatment of prostate cancer by Neal D. Shore

    Published 2013-02-01
    Get full text
    Article
  2. 2
    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36

    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs... by Neal D. Shore

    Published 2022-12-01
    Get full text
    Article
  3. 3
    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists by Mohamad Moussa, Mohamad Abou Chakra, Neal D. Shore, Athanasios Papatsoris, Yasser Farahat, Michael A. O’Donnell

    Published 2024-03-01
    Get full text
    Article
  4. 4
    Mechanism of action of nadofaragene firadenovec-vncg

    Mechanism of action of nadofaragene firadenovec-vncg by Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, Neal D. Shore, Grannum R. Sant, Badrinath R. Konety

    Published 2024-03-01
    Get full text
    Article
  5. 5
    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local th... by Martin Gleave, Brad Rosbrook, Stephen J Freedland, Qi Shen, Jennifer Sugg, Gabriel P Haas, Neal D Shore

    Published 2021-08-01
    Get full text
    Article
  6. 6
    Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

    Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer by Fred Saad, Daniel J. George, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, Bertrand Tombal, Neal D. Shore

    Published 2023-10-01
    Get full text
    Article
  7. 7
    Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects

    Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects by Daniel Saltzstein, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang, E. David Crawford

    Published 2018-02-01
    Get full text
    Article
  8. 8
    Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

    Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials by Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev, Scott C. Flanders

    Published 2018-09-01
    Get full text
    Article
  9. 9
    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerR... by Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal

    Published 2023-06-01
    Get full text
    Article
  10. 10
    Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

    Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi) by Herjan J.T. Coelingh Bennink, Jeroen A. van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, Gonnie van Osta, Jan Krijgh, Neal D. Shore, Fred Saad, Andrew V. Schally, Frans M.J. Debruyne

    Published 2021-06-01
    Get full text
    Article

Search Tools: